{'fraction_non_alphanumeric': 0.0215633423180593, 'fraction_numerical': 0.016172506738544475, 'mean_word_length': 5.405172413793103, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Role of Retrobulbar Liposomal Amphotericin in Orbital Apex Syndrome in a COVID – 19 Positive Diabetic

Coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been seen to have varied presentation affecting multiple organ systems. Mucormycosis is a rapidly progressive disease often seen in immunocompromised patients or those with diabetes mellitus with guarded prognosis. This report is based on an interesting case of a 37-year-old man with orbital apex syndrome secondary to mucormycosis and co-infection with COVID-19. We discuss the benefit of administering liposomal amphotericin via retrobulbar injection in addition to systemic antifungals in the setting of rhino-orbital-mucormycosis.